Compare VREX & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | ZVRA |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.5M | 689.4M |
| IPO Year | 2016 | 2015 |
| Metric | VREX | ZVRA |
|---|---|---|
| Price | $18.41 | $9.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $18.90 | ★ $25.00 |
| AVG Volume (30 Days) | 457.5K | ★ 744.9K |
| Earning Date | 11-17-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | 0.23 | ★ 0.74 |
| Revenue | ★ $811,000,000.00 | $106,470,000.00 |
| Revenue This Year | $2.52 | $43.97 |
| Revenue Next Year | $3.97 | $15.93 |
| P/E Ratio | $80.07 | ★ $14.00 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $9.09 | $8.01 |
| 52 Week High | $18.63 | $15.04 |
| Indicator | VREX | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 36.35 |
| Support Level | $18.35 | $9.29 |
| Resistance Level | $18.63 | $11.19 |
| Average True Range (ATR) | 0.05 | 0.46 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 36.67 | 3.61 |
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.